Comparing a new drug to standard hormone therapy for advanced prostate cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new pill, opevesostat, against other hormone treatments for men with metastatic castration-resistant prostate cancer that has progressed after previous therapies. It aims to see which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to other parts of the body (like bones or soft tissue).
- Your cancer has grown while on hormone therapy, and you've tried one newer hormone drug.
- You have had 1 or 2 chemotherapy treatments for your prostate cancer, and it has continued to grow.
- Your testosterone level is very low (below 50 ng/dL).
- You need to provide a fresh tumor sample from a soft tissue site that hasn't been treated with radiation.
- You are able to be active and take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
This trial tests a new drug called BNT324 against the standard chemotherapy docetaxel for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the new treatment can help control the cancer better.
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
This trial tests a new oral drug, XNW5004, for men with advanced prostate cancer that has spread or stopped responding to standard treatments. It may be given alone or with other therapies like abiraterone, enzalutamide, or chemotherapy, and aims to find better ways to control the disease.
Hear when a new Prostate Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.